At ViiV Healthcare our goal is clear: to end the HIV epidemic. Building on our long-standing experience in HIV and leadership in long-acting innovation, we are developing the next generation of HIV prevention and treatment options to meet the evolving needs of people living with HIV and those who benefit from PrEP (Pre-Exposure Prophylaxis).
Our industry-leading pipeline reflects our “INSTI at the core” approach. We have a successful track record of developing and launching medicines centred on integrase strand transfer inhibitors (or integrase inhibitors or INSTIs) for the treatment and prevention of HIV. We continue to explore new ways to combine INSTIs with other compounds – including broadly neutralising antibodies (bNAbs) or capsid inhibitors – to investigate longer dosing intervals.
We have a number of potential medicines in development for both the treatment and prevention of HIV, including the first third-generation INSTI candidate and ultra-long-acting (dosing intervals of four months or longer) options being investigated across adult and paediatric populations:
CLINICAL DEVELOPMENT PIPELINE
Compound number / Generic name / Brand name |
Indication |
Phase |
Mode of action / Vaccine type |
|---|---|---|---|
| VH3810109 ✝ | HIV |
Phase II |
HIV broadly neutralising antibody |
| VH4011499 | HIV | Phase II | HIV capsid protein inhibitor |
| VH4524184 ✝ | HIV | Phase II | HIV integrase inhibitor |
| GSK1265744 cabotegravir |
HIV | Phase I | HIV integrase inhibitor |
✝In-license or other alliance relationship with third party
PIPELINE PROGRESS
Our development pipeline evolves as new projects progress from research into clinical development. Products in development progress through three stages, phase I, phase II, and phase III/registrational, allowing us to assess their safety, efficacy. At every stage, we are focused on advancing cutting-edge science for the communities we serve. Our commitment to understanding the impact of our medicines extends beyond clinical trials. Learn how we study their real-world use after approval.
Compassionate use
Read more about our commitment to compassionate use within HIV clinical trials
.jpg?auto=format)
YOU MAY ALSO BE INTERESTED IN
An exciting and relatively new area of research in the development of next generation HIV treatments involves broadly neutralising antibodies (bNAbs).
The process of identifying, creating and developing generally well-tolerated and effective innovative HIV therapies is complex and requires ongoing collaboration between research teams that work in many different areas of medicines development.
We’ve got more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations to broaden our capabilities and enhance our performance.
NP-GBL-HVX-WCNT-230031 February 2026.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
